TechBio News 🪩 (II)
Latest Trends: Cosmo Pharmaceuticals, April19 Discovery, SandboxAQ, drug2drugs by Fujifilm, Coeptis Therapeutics, Insilico Medicine, Charles River and Vamstar
This is part II of today’s Weekly TechBio newsletter.
Latest Trends: Latent Labs, Algorithmiq, NVIDIA, eXoZymes, Agilisium, ABVC and BioKey, Hill Research and Aikium
▶️ TechBio News (II)
Latest Trends: Cosmo Pharmaceuticals, SandboxAQ, drug2drugs by Fujifilm, Galixir, Coeptis Therapeutics, Insilico Medicine, Charles River and Vamstar
Latest Trends: Aimble, AI Proteins, Psivant Therapeutics, Nabla Bio, Arpeggio BioSciences, Nano-X Vision, WhiteLab Genomics and Almirall
🌀 AI-Designed Enzymes by
Researchers at the Institute for Protein Design have made a computationally-designed, multi-step enzyme.
A new paper, published today in Science, suggests a way forward.
David Baker’s group at the Institute for Protein Design has developed a method to computationally design serine hydrolases, a class of enzymes involved in everything from blood clotting, digestion, and nerve signaling. Their study not only demonstrates the feasibility of designing this class of enzymes, but also provides a roadmap for creating other types of dynamic, moving proteins.
TechBio News (II)
🪩 Cosmo Pharmaceuticals N.V. (SIX: COPN)
On February 11, 2025, Cosmo Pharmaceuticals announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo’s commitment to integrating AI as a core strategic pillar in its future growth and innovation roadmap (Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio).
Andrea has been pivotal in the development and commercialization of Cosmo’s Intelligent Medical Devices (a division of Cosmo Pharmaceuticals developing cutting-edge Intelligent Medical Devices) GI Genius™, the world’s first AI-powered polyp detection system in gastroenterology. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications.
In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy. This includes, among others:
Gastroenterology Pipeline: Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders.
Dermatology Pipeline: Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula® and other dermatological innovations.
AI-Enabled Drug Discovery & Development: Expanding AI’s role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo’s position as a leader in AI-driven healthcare solutions.
Cosmo Pharmaceuticals N.V. (SIX: COPN) is a Swiss-based specialty pharmaceutical company listed on the SIX Swiss Exchange. The company focuses on developing and commercializing innovative pharmaceutical products, primarily in the areas of gastroenterology (with products aimed at treating conditions like irritable bowel syndrome, IBS, inflammatory bowel disease, IBD and other gastrointestinal disorders), dermatology and oncology. Cosmo is well-known for its expertise in drug delivery technologies, particularly in the development of formulations that enhance the absorption and efficacy of active pharmaceutical ingredients. Cosmo specializes in proprietary drug delivery systems, such as its "Lipid Matrix Technology" and "Gastric Retention Technology," which are designed to optimize drug release and absorption in the gastrointestinal tract (MMX® technology and its applications in gastrointestinal diseases).
A bold new chapter of AI, community, and revenue diversification.